P4‐220: Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): Post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease | Zendy

Graham Stephen | Zendy; Hendrix Suzanne | Zendy; Miller Michael | Zendy; Pejovic Vojislav | Zendy; Tocco Michael | Zendy

Premium

P4‐220: Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): Post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease

Author(s) -

Graham Stephen,

Hendrix Suzanne,

Miller Michael,

Pejovic Vojislav,

Tocco Michael

Publication year - 2011

Publication title -

alzheimer's and dementia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.713

H-Index - 118

eISSN - 1552-5279

pISSN - 1552-5260

DOI - 10.1016/j.jalz.2011.05.2245

Subject(s) - memantine , placebo , post hoc analysis , medicine , percentile , randomized controlled trial , disease , dementia , pathology , statistics , alternative medicine , mathematics

MEMANTINE (28 MG, ONCE DAILY): POST HOC RESPONDER ANALYSIS FROM A RANDOMIZED TRIAL IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER’S DISEASE Stephen Graham, Suzanne Hendrix, Michael Miller, Vojislav Pejovic, Michael Tocco, Forest Reseach Institute, Jersey City, New Jersey, United States; 2 Pentara Corporation, Salt Lake City, Utah, United States; 3 Prescott Medical Communications Group, Chicago, Illinois, United States; 4 Forest Research Institute, Jersey City, New Jersey, United States.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research